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Treatment of Scedosporium apiospermum central nervous system (CNS) infection typically consists of an azole in combination with
surgical debridement. This approach requires prolonged treatment and carries a high associated mortality. We present two cases of
the successful treatment of S. apiospermum CNS infections with the combination of voriconazole and terbinafine.
1. Case Reports
1.1. Case 1. An 81-year-old Hispanic woman with a past med-
ical history significant for hypertension, diabetes mellitus,
hypothyroidism, and chronic kidney disease presented with
symptoms of sinusitis, including facial pain, nasal congestion,
and rhinorrhea. The sinusitis was later complicated by the
development of left orbital cellulitis.The patient underwent a
functional endoscopic sinus surgery (FESS) without evidence
of gross infection and was treated with oral levofloxacin.
Three weeks later, her orbital cellulitis resolved; however,
she developed nausea, vomiting, headaches, left vision loss,
diplopia, and local pain. Her eye exam was significant
for intact extraocular movements, no nystagmus, and a
positive afferent pupillary defect. No periorbital edema or
erythema was observed. Visual acuity for her right eye was
20/60 and for her left eye was 20/100. Her basic laboratory
results were normal. She was diagnosed with a left orbital
complex syndrome with optic neuropathy and underwent
another FESS with sinusotomy and debridement.The patient
was briefly placed on intravenous (IV) steroids, and she
was discharged home on an oral prednisone taper and
levofloxacin. However, the patient was readmitted 10 days
later with worsening vision loss on the left; she was then
only able to perceive light. The intraoperative cultures from
her last FESS grew a moderate amount of mold, which
was subsequently identified as Scedosporium apiospermum
based on its characteristic macroscopic morphology and
conidiation. Susceptibility testing of the isolate revealed a
voriconazole MIC of 0.5 ug/mL. An orbital MRI revealed
mildly elevated signal within the intraorbital segment of the
left optic nerve, mild inflammatory changes surrounding
the optic nerve sheath complex and the orbital apex, and
very mild asymmetric prominence of the left extraocular
muscles concerning for myositis (Figure 1). The patient was
placed on IV voriconazole at 6mg/kg every 12 hours for a
presumed fungal sinusitis, myositis, and possibly sinus fungal
osteomyelitis. After approximately 30 days of IV voriconazole
therapy, the patient was transitioned to oral voriconazole
and had obtained a voriconazole trough level of 2.06 ug/mL
a month later. Two months after antifungal therapy was
initiated, the patient presented with worsening headache,
nausea, vomiting, and anorexia, and a repeat orbital MRI
showed new mild left proptosis, enhancing soft tissue at the
orbital apex extending along the cavernous sinus and under
both frontal lobes along the dura, and slightly increased
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Figure 1: Orbital MRI. Orbital MRI revealed mildly elevated
signal within the intra-orbital segment of the left optic nerve,
mild inflammatory change surrounding the optic nerve sheath and
very mild asymmetric prominence of the left extra-ocular muscles
concerning for myositis (arrows).
Figure 2: Brain MRI. Ventriculomegaly, increased halo surround-
ing the lateral ventricles, and debris within the ventricles with
restricted diffusion and ependymal and subependymal enhance-
ment (arrows).
mucosal thickening throughout the sinuses with moderate
to severe involvement of the left sphenoid and right max-
illary sinus. The patient was evaluated for possible surgical
debridement; however, due to the complexity of the disease
location, it was decided to proceedwithmedicalmanagement
only. Due to the rapid progression of her disease, renally
dosed oral terbinafine was added at a dose of 250mg daily.
After 4 months of combination therapy, repeat orbital MRI
showed stable inflammatory changes without progression.
Thepatient’s clinical status eightmonths later is stable with no
further CNS symptoms and good tolerance of her antifungal
regimen.
1.2. Case 2. A 64-year-old White man with a previous diag-
nosis of eosinophilic pneumonia, which had been treated
with high-dose steroids, cyclophosphamide, and mycophe-
nolic acid, presented with subacute symptoms of headaches,
fevers, aphasia, and ataxia.Hewas diagnosedwithmeningitis,
cerebritis, and ventriculitis based on an elevated cell count in
his cerebral spinal fluid (CSF) and consistent imaging; how-
ever, the etiology was unclear. He was treated with antibac-
terial therapy, including a 10-day course of vancomycin,
cefepime, and ampicillin, with partial resolution of his
symptoms. He had a negative infectious workup including a
negative brain biopsy, aswell as, a normal cerebral angiogram.
A CT scan of the head demonstrated hydrocephalus, and
he had an external ventricular drain placed. A month later,
Figure 3: H&E stain of the Brain Biopsy. Clusters of amorphous
linear structures with a morphology simulating fungal hyphae.
his mental status worsened. At that time, his vital signs
were normal and his neurologic exam was notable for mild
confusion. Cranial nerves II through XII were intact with the
exception of slow saccades, but no nystagmus was present.
Laboratory studies were remarkable for a slightly elevated
white blood cell count (WBC) of 12.2 × 103/uL (normal
range: 4.5–11.0 × 103/uL) and a decreased hematocrit (Hct)
of 29.1% (normal range: 42–54%). A repeat evaluation of his
CSF showed 326 WBC (normal range: 0–5 × 106/L) with
83% neutrophils (normal range: 0–6%). His CSF protein
was 113mg/dL (normal range: 15–45mg/dL) and glucose was
54mg/dL (normal range: 40–80mg/dL). Gram stain and bac-
terial cultures were negative. An extensive infectious workup
was negative including, CSF AFB smear and culture, serum
and CSF cryptococcal antigen, Toxoplasma gondii antibody,
Parvovirus B19 antibody, CSF VDRL, CSF and serum PCR
for HHV-6, EBV, HSV-1/2, CMV, WNV, enterovirus, and JC
virus. An MRI of his brain revealed ventriculomegaly, an
increased halo surrounding the lateral ventricles, and debris
within the ventricles with restricted diffusion and ependymal
and subependymal enhancement (Figure 2). A repeat brain
biopsy showed fungal-like elements (Figure 3). His CSF fun-
gal cultures subsequently grew Scedosporium apiospermum.
He was then started on oral voriconazole 600mg twice daily
and terbinafine 250mg twice daily due to the severity of the
infection. Two weeks later the voriconazole trough level was
2.58 ug/mL. His mental status improved substantially. Three
months later, repeat CSF studies showed 3 WBC (normal
range: 0–5 × 106/L) with 3% neutrophils (normal range:
0–6%). His CSF protein was 42mg/dL (normal range: 15–
45mg/dL) and glucose was 60mg/dL (normal range: 40–
80mg/dL). Repeat CSF fungal cultures were negative. In light
of his dramatic improvement, terbinafine was stopped and he
continued on voriconazole only with regular monitoring of
his drug level. Unfortunately, two months later the patient
presented again with fevers and confusion, and his CSF
cultures grew Scedosporium apiospermum. His clinical course
was then complicated by influenza pneumonia, pulmonary
embolism, ventricular drain malfunction, and renal failure.
The patient failed to improve and ultimately was discharged
to hospice and died one month later.
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2. Discussion
Scedosporium apiospermum, the anamorphic (asexual state)
of Pseudallescheria boydii, is a ubiquitous organism with a
worldwide distribution [1, 2]. This organism is most com-
monly associated with localized cutaneous and subcutaneous
infections of the lower extremities after traumatic penetration
with contaminatedmaterial (Madura foot) but can also cause
disease at other sites such as the lung, brain, bone, eye, sinuses
and joints [3–5]. Invasive and disseminated disease present-
ing with severe pneumonia, CNS infection, and endocarditis
has been described in immunocompromised hosts, where the
respiratory tract has been identified as the main major portal
of entry [6–8]. In a review of 23 S. apiospermum infections
in solid organ transplant recipients between 1976 and 1999,
8 patients developed dissemination, 11 had invasive lung
disease, and 11 had CNS involvement, including 10 patients
with brain abscesses [9]. In another series, almost 60% of
39 culture-proven cases of S. apiospermum infections of the
CNS presented with an underlying immune impairment
(immunosuppressive drugs, antineoplastic chemotherapy, or
with a medical immune deficiency) [10]. In an Australian
retrospective review of Scedosporium infections, S. apiosper-
mum demonstrated invasiveness in 6% of cases, whereas
S. prolificans was invasive in 36% of cases [11]. Regarding
antifungal susceptibility, in vitro data suggest that the two
antifungals with the best activity against S. apiospermum are
voriconazole and micafungin [12]. Voriconazole has shown
clinical efficacy and good tolerance in the management of
Scedosporium spp. infections [13].Measurements of voricona-
zole levels have been shown to be an effective method to
improve efficacy and safety in this setting [14, 15]. Although
in vitro data for terbinafine have shown high MICs against
Scedosporium spp.; MICs in the literature are variable [16, 17],
activity has been noted for some of the isolates [18, 19],
and in vitro synergy between azoles and terbinafine has
been reported for S. prolificans [17]. Likewise, terbinafine
and voriconazole have been used successfully as combination
therapy in the treatment of invasive S. apiospermum [20–
23] and S. prolificans [24–26]. There is also a report of
successful treatment of S. apiospermum with voriconazole
in combination with caspofungin [27] or with posaconazole
alone [28].
Predisposing factors for progressive fungal CNS infection
in the first case we presented included advanced age, previous
antibiotic and steroid exposure, the presence of diabetes mel-
litus and recent sinus instrumentation. As an alternative to
terbinafine, an IV echinocandin could have been considered
in combination with oral voriconazole in this case, but the
likelihood of a prolonged, and possibly lifelong, treatment
course made IV administration less feasible. The second
patient had intense immunosuppressive therapy as his main
predisposing factor for progressive fungal CNS infection. He
clearly had a notable improvement with normalization of
CSF cell counts and CSF sterilization while on combination
antifungal therapy; however, due to his multiple comorbidi-
ties and a prolonged hospitalization, the infection relapsed
and he died. Although successful reports of this antifun-
gal combination have been described in the treatment of
S. prolificans [24–26, 29], to our knowledge this is only the
third case report of the successful use of the combination
of voriconazole and terbinafine in the treatment of invasive
CNS Scedosporium apiospermum infection. This treatment
combination should be considered in cases of severe CNS
infection with Scedosporium apiospermum, where surgical
options are limited, and/or there has been a suboptimal
response to voriconazole monotherapy.
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